enzymatic activity Search Results


enzymatic method for estimating amylase activity  (Rauscher GmbH)
90
Rauscher GmbH enzymatic method for estimating amylase activity
Enzymatic Method For Estimating Amylase Activity, supplied by Rauscher GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enzymatic+activity/enzymatic+method+for+estimating+amylase+activity/10__4314_slash_jasem__v21i5__15-107-5-8
Average 90 stars, based on 1 article reviews
enzymatic method for estimating amylase activity - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
horseradish peroxidase  (Sinopharm ltd)
90
Sinopharm ltd horseradish peroxidase
Horseradish Peroxidase, supplied by Sinopharm ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enzymatic+activity/horseradise+peroxidase++hrp++enzymatic+activity++250+u+mg/pmc10597545-36-20-37
Average 90 stars, based on 1 article reviews
horseradish peroxidase - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
interactions between enzymes and oxide colloidal particles and their influence on enzymatic activity  (VDI Verlag GmbH)
90
VDI Verlag GmbH interactions between enzymes and oxide colloidal particles and their influence on enzymatic activity
Interactions Between Enzymes And Oxide Colloidal Particles And Their Influence On Enzymatic Activity, supplied by VDI Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enzymatic+activity/interactions+between+enzymes+and+oxide+colloidal+particles+and+their+influence+on+enzymatic+activity/pm40062453-512-1-16
Average 90 stars, based on 1 article reviews
interactions between enzymes and oxide colloidal particles and their influence on enzymatic activity - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
enzymatic activity assay  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare enzymatic activity assay
Enzymatic Activity Assay, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enzymatic+activity/enzymatic+activity+assay/10__1172_slash_jci23073-240-8-20
Average 90 stars, based on 1 article reviews
enzymatic activity assay - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
enzymatically active pr-vpr fusion protein  (ACADEMIC PRESS INC)
90
ACADEMIC PRESS INC enzymatically active pr-vpr fusion protein
Enzymatically Active Pr Vpr Fusion Protein, supplied by ACADEMIC PRESS INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enzymatic+activity/enzymatically+active+pr+vpr+fusion+protein/pm08623547-22-8-26
Average 90 stars, based on 1 article reviews
enzymatically active pr-vpr fusion protein - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
prostate specific antigen, enzymatically active from human seminal fluid (psa)  (Merck KGaA)
90
Merck KGaA prostate specific antigen, enzymatically active from human seminal fluid (psa)
Prostate Specific Antigen, Enzymatically Active From Human Seminal Fluid (Psa), supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enzymatic+activity/prostate+specific+antigen++enzymatically+active+from+human+seminal+fluid++psa+/pm34954416-66-7-13
Average 90 stars, based on 1 article reviews
prostate specific antigen, enzymatically active from human seminal fluid (psa) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
gcase enzymatic activity assay  (XenoGesis Limited)
90
XenoGesis Limited gcase enzymatic activity assay
Gene therapy rescues the K14-lnl/lnl model in a dose-dependent fashion. (A) Kaplan–Meier survival curve. Data expressed as percentage of survival. (B) body weight expressed as average weight of each cohort/week. (C) difference in average body weight compared to WT (dotted line) at 8 weeks. Data expressed as average weight ± 95% CI. (D) <t>GCase</t> <t>enzymatic</t> activity in plasma 1 month post-administration. Data presented as single data points and mean. (E) GCase enzymatic activity in plasma at end-stage collection point. Data presented as single data points and mean. * indicates statistically significant difference between the experimental group and WT controls; # indicates statistically significant difference between the experimental group and untreated KO controls. P values and statistical tests are reported in .
Gcase Enzymatic Activity Assay, supplied by XenoGesis Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enzymatic+activity/gcase+enzymatic+activity+assay/pmc11336133-262-0-8
Average 90 stars, based on 1 article reviews
gcase enzymatic activity assay - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
enzymatically-active firefly luciferase  (Promega)
90
Promega enzymatically-active firefly luciferase
Gene therapy rescues the K14-lnl/lnl model in a dose-dependent fashion. (A) Kaplan–Meier survival curve. Data expressed as percentage of survival. (B) body weight expressed as average weight of each cohort/week. (C) difference in average body weight compared to WT (dotted line) at 8 weeks. Data expressed as average weight ± 95% CI. (D) <t>GCase</t> <t>enzymatic</t> activity in plasma 1 month post-administration. Data presented as single data points and mean. (E) GCase enzymatic activity in plasma at end-stage collection point. Data presented as single data points and mean. * indicates statistically significant difference between the experimental group and WT controls; # indicates statistically significant difference between the experimental group and untreated KO controls. P values and statistical tests are reported in .
Enzymatically Active Firefly Luciferase, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enzymatic+activity/enzymatically+active+firefly+luciferase/pmc06024324-98-11-19
Average 90 stars, based on 1 article reviews
enzymatically-active firefly luciferase - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
ldh enzymatic activity measurement  (AnaSpec)
90
AnaSpec ldh enzymatic activity measurement
Gene therapy rescues the K14-lnl/lnl model in a dose-dependent fashion. (A) Kaplan–Meier survival curve. Data expressed as percentage of survival. (B) body weight expressed as average weight of each cohort/week. (C) difference in average body weight compared to WT (dotted line) at 8 weeks. Data expressed as average weight ± 95% CI. (D) <t>GCase</t> <t>enzymatic</t> activity in plasma 1 month post-administration. Data presented as single data points and mean. (E) GCase enzymatic activity in plasma at end-stage collection point. Data presented as single data points and mean. * indicates statistically significant difference between the experimental group and WT controls; # indicates statistically significant difference between the experimental group and untreated KO controls. P values and statistical tests are reported in .
Ldh Enzymatic Activity Measurement, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enzymatic+activity/ldh+enzymatic+activity+measurement/pmc06824482-66-6-20
Average 90 stars, based on 1 article reviews
ldh enzymatic activity measurement - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
enzymatically active biomimetic micropropellers  (BioMimetic Therapeutics)
90
BioMimetic Therapeutics enzymatically active biomimetic micropropellers
Gene therapy rescues the K14-lnl/lnl model in a dose-dependent fashion. (A) Kaplan–Meier survival curve. Data expressed as percentage of survival. (B) body weight expressed as average weight of each cohort/week. (C) difference in average body weight compared to WT (dotted line) at 8 weeks. Data expressed as average weight ± 95% CI. (D) <t>GCase</t> <t>enzymatic</t> activity in plasma 1 month post-administration. Data presented as single data points and mean. (E) GCase enzymatic activity in plasma at end-stage collection point. Data presented as single data points and mean. * indicates statistically significant difference between the experimental group and WT controls; # indicates statistically significant difference between the experimental group and untreated KO controls. P values and statistical tests are reported in .
Enzymatically Active Biomimetic Micropropellers, supplied by BioMimetic Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enzymatic+activity/enzymatically+active+biomimetic+micropropellers/pm40577644-3505-18-19
Average 90 stars, based on 1 article reviews
enzymatically active biomimetic micropropellers - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
a-protomer (the subunit containing enzymatic activity)  (Biomol GmbH)
90
Biomol GmbH a-protomer (the subunit containing enzymatic activity)
Gene therapy rescues the K14-lnl/lnl model in a dose-dependent fashion. (A) Kaplan–Meier survival curve. Data expressed as percentage of survival. (B) body weight expressed as average weight of each cohort/week. (C) difference in average body weight compared to WT (dotted line) at 8 weeks. Data expressed as average weight ± 95% CI. (D) <t>GCase</t> <t>enzymatic</t> activity in plasma 1 month post-administration. Data presented as single data points and mean. (E) GCase enzymatic activity in plasma at end-stage collection point. Data presented as single data points and mean. * indicates statistically significant difference between the experimental group and WT controls; # indicates statistically significant difference between the experimental group and untreated KO controls. P values and statistical tests are reported in .
A Protomer (The Subunit Containing Enzymatic Activity), supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enzymatic+activity/a+protomer++the+subunit+containing+enzymatic+activity+/pmc02748972-112-9-15
Average 90 stars, based on 1 article reviews
a-protomer (the subunit containing enzymatic activity) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
recombinant, enzymatically active htryptase-β·heparin complex  (Promega)
90
Promega recombinant, enzymatically active htryptase-β·heparin complex
Gene therapy rescues the K14-lnl/lnl model in a dose-dependent fashion. (A) Kaplan–Meier survival curve. Data expressed as percentage of survival. (B) body weight expressed as average weight of each cohort/week. (C) difference in average body weight compared to WT (dotted line) at 8 weeks. Data expressed as average weight ± 95% CI. (D) <t>GCase</t> <t>enzymatic</t> activity in plasma 1 month post-administration. Data presented as single data points and mean. (E) GCase enzymatic activity in plasma at end-stage collection point. Data presented as single data points and mean. * indicates statistically significant difference between the experimental group and WT controls; # indicates statistically significant difference between the experimental group and untreated KO controls. P values and statistical tests are reported in .
Recombinant, Enzymatically Active Htryptase β·Heparin Complex, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/enzymatic+activity/recombinant++enzymatically+active+htryptase+%CE%B2%C2%B7heparin+complex/pmc03318743-49-3-13
Average 90 stars, based on 1 article reviews
recombinant, enzymatically active htryptase-β·heparin complex - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Gene therapy rescues the K14-lnl/lnl model in a dose-dependent fashion. (A) Kaplan–Meier survival curve. Data expressed as percentage of survival. (B) body weight expressed as average weight of each cohort/week. (C) difference in average body weight compared to WT (dotted line) at 8 weeks. Data expressed as average weight ± 95% CI. (D) GCase enzymatic activity in plasma 1 month post-administration. Data presented as single data points and mean. (E) GCase enzymatic activity in plasma at end-stage collection point. Data presented as single data points and mean. * indicates statistically significant difference between the experimental group and WT controls; # indicates statistically significant difference between the experimental group and untreated KO controls. P values and statistical tests are reported in .

Journal: Human Molecular Genetics

Article Title: Comparison of different promoters to improve AAV vector-mediated gene therapy for neuronopathic Gaucher disease

doi: 10.1093/hmg/ddae081

Figure Lengend Snippet: Gene therapy rescues the K14-lnl/lnl model in a dose-dependent fashion. (A) Kaplan–Meier survival curve. Data expressed as percentage of survival. (B) body weight expressed as average weight of each cohort/week. (C) difference in average body weight compared to WT (dotted line) at 8 weeks. Data expressed as average weight ± 95% CI. (D) GCase enzymatic activity in plasma 1 month post-administration. Data presented as single data points and mean. (E) GCase enzymatic activity in plasma at end-stage collection point. Data presented as single data points and mean. * indicates statistically significant difference between the experimental group and WT controls; # indicates statistically significant difference between the experimental group and untreated KO controls. P values and statistical tests are reported in .

Article Snippet: Standard GCase enzymatic activity assay was outsourced to XenoGesis (Nottingham, UK) and performed as previously described [ , ].

Techniques: Activity Assay

Gene therapy ameliorates neuropathology and reduces substrate accumulation in the brain. (A) representative images of brain sections (cortical region S1BF) stained for the macrophagic marker CD68. Scale bar: 100 μm; high magnification inserts: 60 μm. (B) quantification of immunoreactivity of brain sections stained for CD68. (C) representative images of brain sections (cortical region S1BF) stained for the astrocytic marker GFAP. Scale bar: 100 μm; high magnification inserts: 60 μm. (D) quantification of immunoreactivity of brain sections stained for GFAP. (E) representative images of brain sections (cortical region S1BF) stained for the lysosomal marker LAMP1. Scale bar: 100 μm; high magnification inserts: 60 μm. (F) quantification of immunoreactivity of brain sections stained for LAMP1. (G) GCase enzymatic activity in brain homogenates. (H) substrate accumulation (GluCer isoform C18:0) in brain homogenates. All data are presented as single data points and mean. * indicates statistically significant difference between the experimental group and WT controls; # indicates statistically significant difference between the experimental group and untreated KO controls. p values and statistical tests are reported in .

Journal: Human Molecular Genetics

Article Title: Comparison of different promoters to improve AAV vector-mediated gene therapy for neuronopathic Gaucher disease

doi: 10.1093/hmg/ddae081

Figure Lengend Snippet: Gene therapy ameliorates neuropathology and reduces substrate accumulation in the brain. (A) representative images of brain sections (cortical region S1BF) stained for the macrophagic marker CD68. Scale bar: 100 μm; high magnification inserts: 60 μm. (B) quantification of immunoreactivity of brain sections stained for CD68. (C) representative images of brain sections (cortical region S1BF) stained for the astrocytic marker GFAP. Scale bar: 100 μm; high magnification inserts: 60 μm. (D) quantification of immunoreactivity of brain sections stained for GFAP. (E) representative images of brain sections (cortical region S1BF) stained for the lysosomal marker LAMP1. Scale bar: 100 μm; high magnification inserts: 60 μm. (F) quantification of immunoreactivity of brain sections stained for LAMP1. (G) GCase enzymatic activity in brain homogenates. (H) substrate accumulation (GluCer isoform C18:0) in brain homogenates. All data are presented as single data points and mean. * indicates statistically significant difference between the experimental group and WT controls; # indicates statistically significant difference between the experimental group and untreated KO controls. p values and statistical tests are reported in .

Article Snippet: Standard GCase enzymatic activity assay was outsourced to XenoGesis (Nottingham, UK) and performed as previously described [ , ].

Techniques: Staining, Marker, Activity Assay

Biochemical analysis reveals significant increase in GCase enzymatic activity following ubiquitous gene therapy. (A) liver weight expressed as percentage of total body weight. (B) spleen weight expressed as percentage of total body weight. (C) GCase enzymatic activity in liver homogenates. (D) GCase enzymatic activity in spleen homogenates. (E) GCase enzymatic activity in lung homogenates. (F) GCase enzymatic activity in heart homogenates. (G) substrate accumulation (GluCer isoform C24:0) in liver. (H) substrate accumulation (GluCer isoform C24:0) in spleen. (I) substrate accumulation (GluCer isoform C24:0) in lung. (J) substrate accumulation (GluCer isoform C24:0) in liver. All data are presented as single data points and mean. * indicates statistically significant difference between the experimental group and WT controls; # indicates statistically significant difference between the experimental group and untreated KO controls. P values and statistical tests are reported in .

Journal: Human Molecular Genetics

Article Title: Comparison of different promoters to improve AAV vector-mediated gene therapy for neuronopathic Gaucher disease

doi: 10.1093/hmg/ddae081

Figure Lengend Snippet: Biochemical analysis reveals significant increase in GCase enzymatic activity following ubiquitous gene therapy. (A) liver weight expressed as percentage of total body weight. (B) spleen weight expressed as percentage of total body weight. (C) GCase enzymatic activity in liver homogenates. (D) GCase enzymatic activity in spleen homogenates. (E) GCase enzymatic activity in lung homogenates. (F) GCase enzymatic activity in heart homogenates. (G) substrate accumulation (GluCer isoform C24:0) in liver. (H) substrate accumulation (GluCer isoform C24:0) in spleen. (I) substrate accumulation (GluCer isoform C24:0) in lung. (J) substrate accumulation (GluCer isoform C24:0) in liver. All data are presented as single data points and mean. * indicates statistically significant difference between the experimental group and WT controls; # indicates statistically significant difference between the experimental group and untreated KO controls. P values and statistical tests are reported in .

Article Snippet: Standard GCase enzymatic activity assay was outsourced to XenoGesis (Nottingham, UK) and performed as previously described [ , ].

Techniques: Activity Assay